Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®)

[1] Gianni AM(1989)Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation Lancet 2 580-585

[2] Siena S(2002)Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma J Clin Oncol 20 2453-2463

[3] Bregni M(2002)Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma J Clin Oncol 20 3262-3269

[4] Tarella C(2004)Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study Blood 103 4429-4431

[5] Stern AC(2004)Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma Clin Lymphoma 5 98-101

[6] Pileri A(2004)Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma and mild thrombocytopenia Cancer Biother Radiopharm 19 478-481

[7] Witzig TE(2003)Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma J Clin Oncol 21 1263-1270

[8] Gordon LI(2007)Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin’s lymphoma Cancer Biother Radiopharm 22 684-691

[9] Cabanillas F(2001)Biodistribution and dosimetry results from phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma Crit Rev Oncol Hematol 39 181-194

[10] Czuczman MS(2003)Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials J Nucl Med 44 465-474

[1] Gianni AM(1989)Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation Lancet 2 580-585

[2] Siena S(2002)Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma J Clin Oncol 20 2453-2463

[3] Bregni M(2002)Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma J Clin Oncol 20 3262-3269

[4] Tarella C(2004)Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study Blood 103 4429-4431

[5] Stern AC(2004)Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma Clin Lymphoma 5 98-101

[6] Pileri A(2004)Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma and mild thrombocytopenia Cancer Biother Radiopharm 19 478-481

[7] Witzig TE(2003)Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma J Clin Oncol 21 1263-1270

[8] Gordon LI(2007)Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin’s lymphoma Cancer Biother Radiopharm 22 684-691

[9] Cabanillas F(2001)Biodistribution and dosimetry results from phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma Crit Rev Oncol Hematol 39 181-194

[10] Czuczman MS(2003)Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials J Nucl Med 44 465-474